PT-141 contraindications: who should not use bremelanotide

Last updated 2026-07-25

What is PT-141 actually approved to treat?

PT-141 is the research name for bremelanotide, sold under the brand Vyleesi. The FDA approved it in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, making it only the second drug ever approved in the US for low sexual desire in women, after flibanserin ^[1]. "Acquired" means the low desire wasn't always present, it developed after a period of normal desire. "Generalized" means it isn't tied to one partner or one specific situation. That distinction matters for contraindications, because the drug was tested in a specific population, women aged 18 to 59 in two Phase 3 trials (RECONNECT), and the safety data only really speaks for that group ^[2]. It's not approved for men, it's not approved for postmenopausal women, and it's not approved for low desire caused by a relationship problem, a medical condition, or another drug. Off-label use happens, but the contraindications below were established in that specific patient population, so extrapolating safety to other groups is a real leap, not a formality.

Who should not use PT-141? (Absolute contraindications)

The two contraindications called out most consistently in the clinical literature are uncontrolled hypertension and known cardiovascular disease ^[3][4]. Bremelanotide activates melanocortin 4 receptors in the brain, and that same central pathway also nudges blood pressure and heart rate upward for several hours after a dose ^[5]. In trial data, bremelanotide produced measurable, transient increases in blood pressure and heart rate after dosing, which is exactly why the drug carries specific warnings around cardiovascular risk ^[3]. For someone whose blood pressure is already poorly controlled, or who has a history of heart attack, stroke, or arrhythmia, adding a drug that reliably pushes blood pressure up for a few hours is not a small ask. A review in Drug and Therapeutics Bulletin was blunt about this tradeoff, arguing that regulators leaned on precedent from other approvals rather than a strong independent efficacy signal, while cardiovascular caution was treated almost as an afterthought ^[6]. That's a minority, critical view in the literature, but it's a fair one to weigh: the benefit is modest, so any added risk should be taken seriously rather than waved off. Practically, if you have uncontrolled high blood pressure, established cardiovascular disease, or any condition where a temporary BP spike is genuinely dangerous, this isn't the drug to start without a real conversation with your prescriber first. That conversation should include a look at your actual numbers, more than a checkbox. For anyone tracking their numbers around treatment, PT-141 and blood work covers what's worth checking before and during use.

Does PT-141 raise blood pressure? How much, and for how long?

Yes. Blood pressure increases are a recognized, dose-related effect of bremelanotide, and they show up in the pharmacology data collected across the clinical development program ^[3]. The rise is transient, tied to the hours right after dosing, not a permanent shift in baseline blood pressure. This is a direct consequence of the drug's mechanism. Bremelanotide is a melanocortin receptor agonist acting in the central nervous system, and melanocortin signaling is tied into pathways that regulate appetite, energy balance, and cardiovascular tone, more than sexual response ^[7]. That's a very different mechanism from something like sildenafil, which works locally on vascular smooth muscle. PT-141 works upstream, in the brain, which is also why its side effect profile looks nothing like a PDE5 inhibitor's. The practical takeaway: anyone with borderline or unmanaged hypertension should get their blood pressure controlled and confirmed stable before considering bremelanotide, and should expect some monitoring rather than a one-and-done prescription.

Is PT-141 safe with heart disease, arrhythmia, or a history of stroke?

This is squarely in contraindication territory. It's the same reasoning as the hypertension warning: a temporary rise in blood pressure and heart rate is a bigger deal in someone whose cardiovascular system is already compromised ^[3][4]. A 2022 review focused specifically on managing female sexual dysfunction in the context of hypertension and broader cardiovascular risk, underscoring that clinicians treating desire disorders need to screen for cardiovascular disease before reaching for bremelanotide, not after ^[8]. If you've had a heart attack, a stroke, unstable angina, or you're living with arrhythmia that isn't well controlled, this drug sits outside the population it was tested in and outside the population it should be prescribed to without specialist input. This is also where self-sourcing outside a provider relationship becomes genuinely risky rather than just legally gray. A prescriber who knows your cardiac history is the entire safety mechanism here.

Can you use PT-141 while pregnant or breastfeeding?

No. Bremelanotide is not approved for use during pregnancy, and it isn't studied for safety in that setting the way its efficacy is studied in the RECONNECT trials for HSDD ^[2]. It also isn't intended for postmenopausal women or for anyone outside the approved premenopausal, HSDD-specific indication in the first place, so pregnancy sits well outside any tested use case. If pregnancy is a possibility, or you're breastfeeding, this isn't a drug to experiment with. The honest answer here is that the absence of safety data is itself the reason to avoid it, not a technicality.

What are the most common side effects, and are they dangerous?

Nausea is the single most common side effect, and it's not rare. Across the clinical development program, nausea was reported frequently enough that it's treated as an expected, mechanism-linked effect rather than an occasional nuisance ^[3][9]. Flushing is the second most consistent complaint, along with injection site reactions, headache, and vomiting in a smaller share of users ^[3][10]. Here's the honest framing: nausea and flushing are common, genuinely unpleasant for some users, and a real reason people stop the drug, but they are not the same category of risk as the cardiovascular contraindications above. Nausea is unpleasant. Uncontrolled hypertension plus a BP-raising drug is a different kind of problem. | Side effect | Frequency pattern reported | Why it happens |

Why is PT-141's mechanism different from sildenafil or other ED drugs?

This is the single most useful thing to understand about PT-141, and it explains most of the contraindication logic. Sildenafil and similar PDE5 inhibitors work locally, on vascular smooth muscle, increasing blood flow to genital tissue directly. Bremelanotide works centrally, in the brain, as a melanocortin receptor agonist, particularly at MC4R, acting on desire and arousal pathways in the central nervous system rather than on local blood vessels ^[5][7]. A CNS Spectrums review on the neurobiology of bremelanotide describes this central action as the basis for its effect on desire in premenopausal women with HSDD, distinct from vascular-acting therapies ^[5]. That's also why bremelanotide doesn't require sexual stimulation to "work" the way PDE5 inhibitors do, and why its side effects (nausea, flushing, BP changes) look neurologic and systemic rather than local and vascular. The melanocortin system isn't a niche pathway either. It's the same receptor family being explored for metabolic disease and obesity treatment, which is part of why bremelanotide's relatives have been studied for effects on body weight, appetite, and energy balance, more than sexual response ^[12][13]. That broader biology is exactly why the cardiovascular contraindications exist: you're not numbing a local reflex, you're nudging a brain system with several downstream effects at once.

Who else should be cautious, even without an absolute contraindication?

A few groups fall into a gray zone worth a real conversation with a prescriber rather than a hard no. People with obesity or a history of metabolic conditions should know that bremelanotide's melanocortin activity overlaps with appetite and weight regulation pathways. Two Phase 1 randomized controlled trials specifically looked at bremelanotide's effect on body weight in obese women, since the drug's mechanism touches the same systems involved in energy balance, more than desire ^[13]. That doesn't make it dangerous for this group by default, but it does mean effects beyond the sexual desire indication are plausible and worth discussing. People using other drugs that affect blood pressure or heart rate deserve a specific check-in with their prescriber, since bremelanotide's own BP effect could stack with other medications rather than existing in isolation. People who need frequent, near-daily use should know the drug was studied and approved around an as-needed dosing model, not a daily one, and pushing frequency up doesn't just mean more efficacy, it likely means more cumulative exposure to the same BP and nausea effects ^[3][4]. Details on realistic frequency and spacing are covered in PT-141 dosage. Athletes subject to drug testing should also check their sport's prohibited list before use, since substances acting on the melanocortin/MSH pathway have drawn scrutiny in some testing contexts; see PT-141 and athletes drug testing for specifics.

How does PT-141 compare to flibanserin on safety grounds?

Flibanserin (Addyi) and bremelanotide (Vyleesi) are the only two FDA-approved drugs for HSDD in the US, but they work through completely different mechanisms and carry different contraindication profiles. Flibanserin is a daily pill with a serious alcohol interaction warning and sedation risk. Bremelanotide is an as-needed injection with a cardiovascular and nausea profile instead. A Drug and Therapeutics Bulletin analysis grouped both drugs together as a case study in what it called "the fallacy of regulatory precedent," arguing that once flibanserin was approved despite a modest efficacy signal, bremelanotide's approval leaned on that precedent rather than standing entirely on its own independent risk-benefit case ^[6]. That's a genuinely critical, minority position in the literature, but it's worth knowing that not every clinician-researcher thinks the approval bar here was as high as it should have been. Separately, a 2024 Journal of Sex Research piece titled "Small Effects, Questionable Outcomes" reanalyzed the Phase 3 data and argued the measured benefit, while statistically real, is modest in absolute terms for many patients ^[14]. None of that makes bremelanotide unsafe. It does mean the contraindications matter more, because the benefit side of the ledger isn't overwhelming enough to justify taking on cardiovascular risk casually.

What did the Phase 3 trials actually find about safety?

The two RECONNECT Phase 3 trials, published in Obstetrics and Gynecology in 2019, are the core evidence behind the FDA approval ^[2]. A subgroup analysis of that same trial data, published in the Journal of Women's Health in 2022, looked at how effects and side effects varied across different patient subgroups within the trial population ^[15]. A dedicated safety profile paper pulled together adverse event data across the full clinical development program, more than the two approval trials, and it's the most direct single source for contraindication and side effect frequency data used throughout this article ^[3]. That's the paper to point to if you want the actual numbers behind nausea, flushing, and blood pressure changes, rather than a summary of a summary. A Phase 2b dose-ranging study also looked at responder rates across different doses, which is part of why the approved dose landed where it did, balancing effect against the side effect burden ^[16]. None of these trials were run in men, postmenopausal women, or people with uncontrolled cardiovascular disease, which is exactly why those groups fall outside confirmed safety data rather than inside it.

What should you tell your prescriber before starting PT-141?

Bring your actual blood pressure numbers, not a guess. Bring a real list of cardiovascular history, including anything that happened years ago, more than current diagnoses. Mention pregnancy plans or breastfeeding status upfront. Mention every other medication and supplement you're taking, especially anything that affects blood pressure or heart rate. A prescriber who has this full picture can actually weigh the modest, real benefit shown in the RECONNECT trials against your personal risk profile ^[2][3]. A prescriber working from a partial picture can't do that job well, and that's true regardless of how the prescription gets written or filled. Bremelanotide Rx works from provider-reviewed information, and if you and a prescriber decide PT-141 is appropriate for you, treatment should run through a licensed provider and a pharmacy partner that fulfills prescriptions under proper oversight, not an unverified seller with no clinical relationship attached.

Is PT-141 legal to buy without a prescription?

Vyleesi, the FDA-approved version, is prescription-only. Bremelanotide as a raw compound has also been the subject of regulatory attention around compounding rules: bulk drug substances used in compounding under Section 503A are governed by a specific FDA list ^[17][18], and pharmacy compounding more broadly is governed by 21 U.S.C. 353a ^[19]. Buying bremelanotide from a source with no prescription and no clinical oversight means skipping the exact screening process, blood pressure checks, cardiovascular history review, pregnancy status, that this entire contraindication list depends on. The contraindications aren't abstract legal language. They're the reason a screening conversation with a real prescriber exists in the first place.

Frequently asked questions

Can men use PT-141?

PT-141 (Vyleesi) is FDA-approved only for premenopausal women with acquired, generalized HSDD ^[1]. It is not approved for men. Any use in men is off-label, and the safety and contraindication data discussed in the approval trials don't cover that population, so the risk profile in men isn't established by the same evidence.

Does PT-141 interact with blood pressure medication?

Bremelanotide itself causes a transient rise in blood pressure and heart rate after dosing ^[3][5]. Combining it with blood pressure medications isn't automatically unsafe, but it's exactly the kind of interaction a prescriber needs to review case by case, since the drug's own cardiovascular effect could compound with other medications.

Can I use PT-141 if I have high blood pressure?

Uncontrolled hypertension is one of the two main contraindications for bremelanotide, alongside known cardiovascular disease ^[3][4]. If your blood pressure is well controlled and stable, this is a conversation for your prescriber, not a decision to make solo, since trial data shows the drug reliably raises BP for hours after each dose.

What does PT-141 do to your heart rate?

Bremelanotide produces a transient, dose-related increase in heart rate along with blood pressure, documented across the clinical development program's safety data ^[3]. This effect is tied to the hours immediately following a dose and is part of why known cardiovascular disease is treated as a contraindication rather than a minor caution.

Is nausea from PT-141 dangerous?

Nausea is the most commonly reported side effect of bremelanotide and is expected, not a sign something has gone wrong ^[3][9]. It's unpleasant for many users and a common reason for discontinuation, but it isn't in the same risk category as the cardiovascular contraindications, and it typically resolves within hours of dosing.

Can PT-141 be used daily?

No. Bremelanotide was studied and approved around as-needed dosing, not daily use ^[3][4]. Using it more frequently than labeled doesn't just add effect, it adds more cumulative exposure to the blood pressure, heart rate, and nausea effects tied to each dose, which is part of why dosing frequency is capped on the label.

Does PT-141 cause skin darkening?

Focal hyperpigmentation, darkening of skin, gums, or facial areas, has been reported with repeated bremelanotide dosing, tied to activity at melanocortin receptors related to melanocyte-stimulating hormone signaling ^[7][11]. It's not universal, but it's a known, mechanism-linked effect worth discussing with a prescriber before long-term use.

Is PT-141 safe during pregnancy?

No. Bremelanotide isn't studied for safety in pregnancy, and it isn't approved for use during pregnancy or breastfeeding ^[2]. The approved indication is specifically premenopausal women with HSDD, and pregnancy sits outside the population studied in the RECONNECT trials, so the honest answer is to avoid it.

How is PT-141 different from Viagra in terms of risk?

Sildenafil (Viagra) works locally on vascular tissue to increase blood flow. Bremelanotide works centrally in the brain as a melanocortin receptor agonist, which is why its side effects (nausea, flushing, transient blood pressure rise) look systemic and neurologic rather than local ^[5][7]. Their contraindication profiles differ accordingly.

Can postmenopausal women use PT-141?

Bremelanotide (Vyleesi) is FDA-approved specifically for premenopausal women with acquired, generalized HSDD ^[1][2]. It is not approved for postmenopausal women, and the trial data doesn't establish safety or efficacy for that group, so use outside the approved population is off-label and not backed by the same evidence.

What happens if PT-141 is combined with alcohol?

The core safety literature on bremelanotide centers on cardiovascular effects and nausea rather than a defined alcohol interaction warning like flibanserin carries ^[3][4][6]. That said, alcohol can independently affect blood pressure and nausea, so combining the two without discussing it with a prescriber isn't advisable.

Who should absolutely not take PT-141?

Uncontrolled hypertension and known cardiovascular disease are the clearest contraindications, given bremelanotide's transient blood-pressure-raising effect ^[3][4]. Pregnancy is also a reason to avoid it, since safety data doesn't cover that population. Anyone outside the approved premenopausal HSDD population should treat use as off-label and unproven for their situation.

Sources

1. PubMed, Bremelanotide: First Approval (Drugs, 2019): Bremelanotide (Vyleesi) was FDA-approved in 2019 for acquired, generalized HSDD in premenopausal women, the second such approval after flibanserin
2. PubMed, Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (Obstetrics and Gynecology, 2019): The RECONNECT Phase 3 trials tested bremelanotide in premenopausal women aged 18-59 with HSDD and form the core efficacy/safety evidence behind approval
3. PubMed, Safety Profile of Bremelanotide Across the Clinical Development Program (Journal of Women's Health, 2022): Nausea, flushing, and transient increases in blood pressure and heart rate are the most consistently reported adverse effects across the full clinical development program
4. PubMed, Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder (The Annals of Pharmacotherapy, 2020): Cardiovascular risk and dosing limits are part of the labeled precautions for bremelanotide following its approval
5. PubMed, The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women (CNS Spectrums, 2022): Bremelanotide acts centrally via melanocortin receptor activity in the CNS, distinct from peripheral vascular mechanisms like PDE5 inhibitors
6. PubMed, Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent (Drug and Therapeutics Bulletin, 2021): A critical analysis argues bremelanotide's approval leaned on regulatory precedent from flibanserin rather than an independently strong risk-benefit case
7. PubMed, Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin (Biomolecules, 2022): Melanocortin receptor biology links central sexual desire pathways with pigmentation and other systemic effects via shared receptor families
8. PubMed, Management of Hypertension with Female Sexual Dysfunction (Medicina, 2022): Clinicians managing female sexual dysfunction need to screen for hypertension and cardiovascular risk before prescribing agents like bremelanotide
9. PubMed, Bremelanotide for Treatment of Female Hypoactive Sexual Desire (Neurology International, 2022): Nausea is documented as the most frequently reported side effect associated with bremelanotide treatment
10. PubMed, An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder (Expert Opinion on Pharmacotherapy, 2023): Injection site reactions are a commonly reported adverse effect tied to the subcutaneous autoinjector delivery method
11. PubMed, Melanocortins in the treatment of male and female sexual dysfunction (Current Topics in Medicinal Chemistry, 2007): Melanocortin agonists related to bremelanotide are linked to melanocyte-stimulating hormone pathways associated with pigmentation changes
12. PubMed, Targeting the central melanocortin system for the treatment of metabolic disorders (Nature Reviews Endocrinology, 2023): The central melanocortin system that bremelanotide acts on is also a target pathway for metabolic and weight-related treatment research
13. PubMed, Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials (Diabetes, Obesity & Metabolism, 2022): Two Phase 1 randomized controlled trials examined bremelanotide's effect on body weight specifically in obese women
14. PubMed, Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder (Journal of Sex Research, 2024): A reanalysis of Phase 3 trial data concludes the measured treatment benefit of bremelanotide is modest in absolute terms
15. PubMed, Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide (Journal of Women's Health, 2022): Subgroup analyses of the RECONNECT trial data examined how efficacy and side effects varied across different patient subgroups
16. PubMed, Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide (The Journal of Sexual Medicine, 2019): A Phase 2b dose-ranging study analyzed responder rates across bremelanotide doses, informing the dose selected for approval
17. eCFR, 21 CFR 216.23 (final 503A Bulks List): Bulk drug substances used in 503A compounding are governed by a specific FDA regulatory list
18. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA maintains and governs which bulk drug substances, including candidates like bremelanotide, may be used under 503A compounding rules
19. Cornell Law/Legal Information Institute, 21 U.S.C. 353a (pharmacy compounding): Pharmacy compounding of drug substances is governed by federal statute 21 U.S.C. 353a